DDInter1662 DDInter53
Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as [Citalopram] and [Fluoxetine]. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects. Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.[A1846,A187075,T28]
Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer and colorectal cancer , are under ongoing investigations. Alpelisib was granted FDA approval on 24 May 2019. In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy.
Sertraline {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Lurasidone
Lurasidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Sertraline {u} (Compound) causes {v} (Side Effect) Hepatobiliary disease
Hepatobiliary disease {u} (Side Effect) is caused by {v} (Compound) Lurasidone
Lurasidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Sertraline {u} (Compound) causes {v} (Side Effect) Galactorrhoea
Galactorrhoea {u} (Side Effect) is caused by {v} (Compound) Carbamazepine
Carbamazepine {u} may lead to a major life threatening interaction when taken with {v} Alpelisib
Sertraline {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Phenobarbital
Phenobarbital {u} may lead to a major life threatening interaction when taken with {v} Alpelisib
Sertraline {u} (Compound) downregulates {v} (Gene) CSRP1
CSRP1 {u} (Gene) is downregulated by {v} (Compound) Dapsone
Dapsone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Sertraline {u} (Compound) upregulates {v} (Gene) INSIG1
INSIG1 {u} (Gene) is upregulated by {v} (Compound) Carvedilol
Carvedilol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Sertraline {u} (Compound) upregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Simvastatin
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Sertraline {u} (Compound) downregulates {v} (Gene) TUBB6
TUBB6 {u} (Gene) is upregulated by {v} (Compound) Mitomycin
Mitomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Sertraline {u} (Compound) upregulates {v} (Gene) INSIG1
INSIG1 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Sertraline {u} (Compound) upregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is bound by {v} (Compound) Atorvastatin
Atorvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Sertraline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lurasidone (Compound) and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Sertraline (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Lurasidone (Compound) and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Sertraline (Compound) causes Galactorrhoea (Side Effect) and Galactorrhoea (Side Effect) is caused by Carbamazepine (Compound) and Carbamazepine may lead to a major life threatening interaction when taken with Alpelisib
Sertraline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Phenobarbital (Compound) and Phenobarbital may lead to a major life threatening interaction when taken with Alpelisib
Sertraline (Compound) downregulates CSRP1 (Gene) and CSRP1 (Gene) is downregulated by Dapsone (Compound) and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Sertraline (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) is upregulated by Carvedilol (Compound) and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Sertraline (Compound) upregulates HMGCR (Gene) and HMGCR (Gene) is bound by Simvastatin (Compound) and HMGCR (Gene) is upregulated by Simvastatin (Compound) and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Sertraline (Compound) downregulates TUBB6 (Gene) and TUBB6 (Gene) is upregulated by Mitomycin (Compound) and Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Sertraline (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene) is downregulated by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Sertraline (Compound) upregulates HMGCR (Gene) and HMGCR (Gene) is bound by Atorvastatin (Compound) and Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib